Login
$FRNM
$10.35 +$0.26 (2.58%) After hours

$FRNM SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 424B3
12 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

– Third-quarter results reflect revenue of $183.5 million driven by the FDA approval of SimpleScreen™ CRC –

29 Oct 2026 SCHEDULE 13G/A
20 Oct 2026 424B3
20 Oct 2026 8-K: Regulation FD Disclosure; Other Events

– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw –

23 Sep 2026 S-8
04 Sep 2026 Form 4: Elliott Aaron Matthew, Director

Gave up 71,920 shares to cover exercise price or tax ($1.1M)

01 Sep 2026 SCHEDULE 13G
27 Aug 2026 EFFECT
27 Aug 2026 424B3
18 Aug 2026 S-1
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G
13 Aug 2026 8-K/A: Completion of Acquisition or Disposition of Assets

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

12 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 SCHEDULE 13G/A
05 Aug 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support